Skip to main content
JIANGSU SIHUAN BIOENGINEERING CO.,LTD logo

JIANGSU SIHUAN BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000518 ISIN · CNE0000001P8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,779 across all filing types
Latest filing 2018-10-30 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 000518

About JIANGSU SIHUAN BIOENGINEERING CO.,LTD

https://www.000518shsw.com

Jiangsu Sihuan Bioengineering Co., Ltd. specializes in the research, development, and production of biopharmaceutical products and traditional Chinese medicines. The company’s core product line features genetic engineering drugs, including recombinant human interleukin-2 (rhIL-2) and recombinant human granulocyte colony-stimulating factor (rhG-CSF). Its manufacturing capabilities encompass various dosage forms such as injections, capsules, and tablets, adhering to rigorous quality standards. In addition to its pharmaceutical core, the company manages ecological restoration and landscape engineering initiatives. The organization focuses on leveraging biotechnology to provide therapeutic solutions for oncology and immune-related conditions, maintaining a commitment to scientific innovation and clinical efficacy.

Recent filings

Filing Released Lang Actions
2018年第三季度报告正文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2018 Third Quarter Report" of 江苏四环生物股份有限公司, indicating it is a quarterly financial report. It contains detailed financial data such as total assets, net profit, cash flow, shareholder information, and financial indicators for the third quarter of 2018. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year confirms it is an Interim / Quarterly Report. The document length is over 7,000 characters and contains substantive financial data, so it is not merely an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR). 9M 2018
2018-10-30 Chinese
2018年前三季度业绩预告
Earnings Release Classification · 95% confidence The document is a performance forecast for the first three quarters of 2018, explicitly labeled as a '业绩预告' (performance forecast or earnings guidance). It provides estimated net profit and earnings per share figures for the period January 1 to September 30, 2018, and compares them to the prior year. It states that the forecast is unaudited and that actual data will be in the 2018 third quarter report. The document is short (1140 characters) and serves as an announcement of expected financial results rather than a full financial report. This matches the definition of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. 9M 2018
2018-10-15 Chinese
2018年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 2018 first extraordinary general meeting (临时股东大会) of Jiangsu Sihuan Bio-Pharmaceutical Co., Ltd. It details the meeting date, voting procedures, attendance, voting results, and legal opinions confirming the validity of the meeting and resolutions. There is no detailed financial data or comprehensive report content. The document is an official announcement of voting results from a shareholder meeting, which fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short (1613 characters), and it is not a full report but a resolution announcement. Therefore, the correct classification is DVA with high confidence.
2018-10-09 Chinese
2018年第一次临时股东大会的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the legality and procedural compliance of a company's 2018 first extraordinary general meeting (临时股东大会). It discusses the convening, voting procedures, attendance, and validity of the meeting and its resolutions. There is no financial data, earnings information, or management discussion of financial results. The document is not an announcement of voting results but a legal opinion on the meeting's legality. This type of document is best classified under Regulatory Filings (RNS) as it is a compliance/legal opinion related to corporate governance and shareholder meeting procedures, not a direct report like AGM materials or voting results announcements.
2018-10-09 Chinese
独立董事意见
Regulatory Filings Classification · 90% confidence The document is a statement of independent directors' opinions regarding a transaction, referencing compliance with governance guidelines and company bylaws. It does not contain financial statements or detailed financial data, nor is it an announcement of a report publication. It is related to governance and board oversight but is not a management report or audit report. The content fits best under Regulatory Filings (RNS) as it is a formal regulatory disclosure about a transaction's fairness and compliance, without being a full report or announcement of voting results.
2018-09-20 Chinese
关于为全资子公司申请银行贷款提供担保
Capital/Financing Update Classification · 95% confidence The document is a formal announcement by Jiangsu Sihuan Bio Co., Ltd. regarding providing a guarantee for a bank loan applied for by its wholly-owned subsidiary. It includes details about the guarantee amount, terms, the subsidiary's financial status, and board approval. The document is relatively short (1524 characters) and focuses on a specific financing-related event (loan guarantee). It does not contain comprehensive financial statements or detailed financial performance data typical of annual or interim reports. It is not a report itself but an announcement about a financing guarantee. Therefore, it fits best under Capital/Financing Update (CAP).
2018-09-20 Chinese

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.